Category #1

New Independent Data on Adherium Smartinhaler™ Clinical Outcomes Shows Increased Adherence and Reduction in Severe Attacks

Adherium_Diagram_v4

September 30, 2015 – Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that data from three independent studies demonstrating the efficacy of the Company’s Smartinhaler™ platform in paediatric asthma management will be presented at the European Respiratory Society International Congress, taking place 26-30 September in Amsterdam, The Netherlands.

 

These clinical outcomes build on the data previously published in Lancet Respiratory Medicine in January 2015, which showed use of the Smartinhaler™ platform increased adherence to preventative medication by 180% and reduced use of reliever medication by 45%¹.

 

Adherium Group Chief Executive Officer, Garth Sutherland said, “These studies clearly show the impact that the application of Adherium’s Smartinhaler™ platform can have on the health outcomes of children with asthma. Most notably, the Sheffield study showed a substantial reduction in the need for oral steroids, indicating a significant reduction in severe attacks, and an increase in lung function”

 

“Asthma can be a debilitating condition and independent studies have consistently demonstrated that our Smartinhaler™ platform can transform the lives of children. These three studies are a valuable contribution to the growing bank of clinical outcomes data which supports the use of Smartinhaler™ medication sensors in improving health outcomes and medication adherence in chronic respiratory disease” he said.

 

The three studies which will be presented as part of Oral Presentation Session 499 Paediatric asthma and allergy: e-health in management, taking place on 30 September are summarised below:

 

Randomised control trial to investigate whether electronic adherence monitoring with reminder alarms and feedback can improve clinical outcomes in childhood asthma
Dr Robert Morton (Clinical Research Fellow, University of Sheffield)
Abstract number: OA4772
Interim data from the study being undertaken at the University of Sheffield has demonstrated that use of the Smartinhaler™ platform substantially increases adherence and significantly reduces the number of oral steroid courses required over the period. The interim data shows that at 12 months:

  • a 144% increase in adherence in the Smartinhaler™ group vs control arm;
  • a 37% reduction in the number of oral steroid courses required in the 12 months from 2.7 to 1.7, a clear marker of reduced severe exacerbations; and
  • a 14.9% increase lung function as measured by FEV1 (mean forced expiratory volume in 1 second % predicted) which increased from 87% to 100%.

 

Exploring the attitudes of adolescents with asthma towards monitoring and sharing of data on their inhaler use
Mr Sam Howard (PhD student, University of Nottingham)
Abstract number: OA4773
This study investigated the attitudes of adolescents with asthma towards an Adherium Smartinhaler™ medication sensor in comparison to existing monitoring methods such as self-reporting.

 

Data from the study showed that both adolescents and parents were significantly positive towards having inhaler use monitored and shared with family or healthcare providers. Interviews with the adolescents showed that adolescents were enthusiastic about utilising the device to prove their independence and demonstrate responsibility for their asthma.

 

Improvement in asthma control and airway inflammation during a period of electronic monitoring
Dr Anja Jochmann (Royal Brompton & Harefield NHS Foundation Trust)
Abstract number: OA4775
Self-assessment of adherence was compared against electronic monitoring via the Smartinhaler™ Platform in a study of 50 children with difficult asthma.

The study demonstrated significant improvement in key indicators following use of Smartinhaler™ including significant improvements in lung function (FEV1), lung inflammation (FENO), and in quality of life questionnaire results (mPAQLQ).

¹Chan AHY, Stewart AWS, Harrison J, Camargo C, Black PN, Mitchell EA. The effect of an inhaler with ringtones on asthma control and school attendance in children. Lancet Respir Med. January 21 2015. http://dx.doi.org/10.1016/S2213-2600(15)00008-9

  • Three independent studies support the positive impact of Smartinhaler™ platform in paediatric asthma
  • 144% increase in adherence, a 14.9% increase in lung function and a 37% reduction in oral steroids indicating reduced severe exacerbations
  • Data disclosed at prestigious European Respiratory Society International Congress in Amsterdam
  • Data disclosed at prestigious European Respiratory Society International Congress in Amsterdam